Discover
01Performance is
our duty
As a preclinical oncology CRO, XenTech believe in expertise, carry innovative values and creative solutions to facilitate and make emerge new efficient tools to fight cancer globally. We’re not in the size or numbers’ race but rather favor precisely targeted tools and services that will provide easier and faster solutions to the oncology research community and ultimately improve patients’ health.
With this spirit we are constantly evolving and prefer focusing on underserved niche (pediatric oncology), accurate models addressing nowadays needs in oncology research (MATCH-R line of PDX reflecting acquired resistance to newly approved or in clinical evaluation drugs) and capitalize on our historic expertise in Breast cancer for which we aim to be THE #1 Reference.
Discover
01They trust us
01Our latest
publications
04.25.25
We’re excited to share our upcoming presentations of two posters at the American Association for Cancer Research (AACR) Annual Meeting 2025, happening April 25-30 in Chicago, IL!
Xentech is willing to accelerate the preclinical development/validation of new anti-cancer therapeutics with a growing panel of highly predictive human tumor-based models and robust screening/profiling studies.
Looking forward to welcoming you at booth #538 or in front of the posters !
Discover
10.23.24
XenTech exhibits at EORTC-NCI-AACR (Barcelona, Oct. 23-25 2024)
We'll be exhibiting at EORTC-NCI-AACR in Barcelona, stop by booth #17 !
Discover
04.05.24
XenTech will be attending AACR Annual Meeting in San Diego (Apr. 5-10 2024)
Olivier, Vincent and Marie cordially invite you to stop by our Booth#3645 to discuss your innovative research projects.
Discover
06.30.23
ITCC-P4, first company in the world to offer preclinical drug tests for children with cancer
Discover
